Related Experiment Videos
Management of cancer in the aged
L Balducci1, G H Lyman, P J Fabri
1Division of Medical Oncology and Hematology, University of South Florida College of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Comprehensive Therapy
|February 1, 1996
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis.
Journal of thrombosis and haemostasis : JTH·2017
Estimated Blood Loss in Group O as Compared to Non-group O Radical Prostatectomy Patients.
Hematology (Amsterdam, Netherlands)·2016
HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line.
In vitro cellular & developmental biology. Animal·2015
Heparin-induced thrombocytopenia and thrombosis.
Comprehensive therapy·2011
Antiplatelet therapy in cardiovascular disease.
Comprehensive therapy·2011
Genetics of cardiovascular disease.
Comprehensive therapy·2011
Septic renal vein thrombosis complicated by septic pulmonary embolism.
Comprehensive therapy·2011
Gout and hyperuricemia.
Comprehensive therapy·2011
Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.
Comprehensive therapy·2010
Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.
Korean journal of radiology·2026
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
Transfusion medicine (Oxford, England)·2026